



Announcement on Completion of signing license agreement with Nippon Gene Material Co., Ltd.

December 20, 2022
Rena Therapeutics Inc.

Rena Therapeutics Inc. (President & CEO: Shuichi Toriya, headquarters: Chiyoda-ku, Tokyo, Japan) announced today that it has executed a non-exclusive license agreement with Nippon Gene Material Co., Ltd. (President: Yuko Yoneda, headquarters: Toyama-shi, Toyama, Japan) enabling the manufacture and sale of Hetero Duplex Oligonucleotide (HDO) research reagents to academic customers in Japan.

With the execution of this agreement, everyone in academia will be able to try HDO widely. HDO is a platform technology for nucleic acid medicine. For example, by binding a ligand for a receptor to the HDO carrier strand, the active strand can be selectively delivered to the target disease site through the binding of this ligand to the receptor expressed on the cell surface. We hope that having a wide range of people in academia try it will expand the possibilities of HDO and lead to more opportunities to use HDO.

If you would like to try HDO, please contact Nippon Gene Material, Sales & Marketing, Jun Kimura (Phone: 076-411-0277 Fax: 076-452-0399 Email: info@nippongenematerial.com HP: <https://www.nippongenematerial.com>).

If you are interested in using HDO for commercial purposes such as drug discovery, you are required to sign a license agreement for the HDO patent. In that case, please contact Rena Therapeutics, Business Development Division, Ryohei Shimizu (Phone: 03-4243-6081 Email: info@renatherapeutics.com).

Outline of Rena Therapeutics Co., Ltd.

Established: January 2015 (Participated in Nippon Shokubai Group in November 2019)

Capital: 100 million yen

Representative: Shuichi Toriya, President & CEO

Location: 1-9-2 Otemachi, Chiyoda-ku, Tokyo

Business description: Provision of basic drug discovery technology related to nucleic acid medicine

Company HP: <https://www.renatherapeutics.com/>